Clinical Trials List
Protocol NumberM25-292
Not yet recruiting
2025-10-01 - 2030-12-24
Phase I
Recruiting3
-
Trial Applicant
AbbVie
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 吳宗哲 Division of Hematology & Oncology
- Ying-Chun Shen Division of Hematology & Oncology
- JIN-YUAN SHIH Division of General Internal Medicine
- Chiun Hsu Division of Hematology & Oncology
- 廖斌志 Division of Hematology & Oncology
- CHAO-CHI HO CHAO-CHI HO Division of General Internal Medicine
- Jih-Hsiang Lee Division of Hematology & Oncology
- YU-YUN SHAO Division of Hematology & Oncology
- 許嘉林 Division of General Internal Medicine
- 廖唯昱 Division of General Internal Medicine
- 呂理駿 Division of Hematology & Oncology
- 徐偉勛 醫學研究部
- 楊景堯 Division of General Internal Medicine
- 蔡子修 Division of General Internal Medicine
- 吳尚俊 Division of General Internal Medicine
- YEN-TING LIN Division of General Internal Medicine
- Chih-Hung Hsu Division of Hematology & Oncology
- James Chih-Hsin Yang Division of Hematology & Oncology
- TSUNG-HAO LIU Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- I-Cheng Lee Digestive System Department
- 齊振達 Digestive System Department
- 吳啟榮 Digestive System Department
- San-Chi Chen Division of Hematology & Oncology
- Yi-Ping Hung Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chih-Yen Tu Division of Thoracic Medicine
- Li-Yuan Bai Division of Hematology & Oncology
- Hung-Wei Wang Digestive System Department
- Chi-Ching Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
28 participants
-
Global
232 participants
